Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Lung

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

To determine the efficacy of MGCD265 in the selected patient population.

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

Phase I/II Study Of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to test the safety of the study drug called MK-3475 in combination with routine care nab-paclitaxel and carboplatin chemotherapy.

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer

The purpose of this study is to Evaluate the safety, tolerability, and DLTs of AGEN1884 in advanced or metastatic cancer (solid tumors or lymphoma) including but not limited to carcinoma, sarcoma, malignant glioma, or melanoma

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

The purpose of this study is to evaluate and compare the effects (good and/or bad) of different targeted study drugs to the standard chemotherapy.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin In Stage IIIb/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer

The purpose of this study is to assess the safety of nivolumab in combination with Abraxane (nab-paclitaxel) based chemotherapy treatments.

Status: Accepting New Patients
Principal Investigator: Aparna Kalyan

A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

The research study is testing the study drug MSB0010718C, given in subjects with solid tumors. Additional purposes of the study are to assess side effects of MSB0010718C and to find out whether MSB0010718C has anti-cancer effects. In addition, we would like to find out how MSB0010718C is processed by the body (this is called pharmacokinetic or PK research). We would also like to learn more about the research participant’s disease and the response to the investigational drug by measuring certain “biomarkers”. “Biomarkers” refer to different types of material/markers found in the blood and tumor tissue that are associated with the disease and/or the research participant’s response to the study drug.

Status: Accepting New Patients
Principal Investigator: Halla Nimeiri

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer

The main goals of the research study are to determine the highest safe dose of veliparib in combination (given together) with carboplatin and etoposide, to understand how the body absorbs and handles veliparib when given together with carboplatin and etoposide, and to evaluate the safety and tolerability of veliparib when taken without the chemotherapy combination.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out what effects, good and/or bad, the treatments used in this study have on patients and their locally advanced, non-operable lung cancer with specific gene alterations (EGFR mutation or ALK rearrangement).

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).

Status: Accepting New Patients
Principal Investigator: Nisha Mohindra

Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

The purpose of this study is to test the safety of giving a few, focused, high doses of radiation (commonly referred to as stereotactic body radiotherapy [SBRT]) to all known sites of cancer within a patient's body.

Status: Accepting New Patients
Principal Investigator: John Hayes

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The main purpose of this study is to find out more about the side effects of MM-121 when combined with docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM-121 with docetaxel or pemetrexed.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

The study will be done in two parts. In Part 1 of the study, patients with lung, colorectal, or head and neck cancer will receive study drug MM-151 in combination with study drug MM-121. The purpose is to determine a safe dose of MM-151 plus MM-121 combination that does not cause unacceptable side effects. This is also referred to as maximum tolerated dose (MTD). MTD will be determined by evaluating the safety and tolerability of MM-151 when combined with MM-121 at different doses. In Part 2 of the study, only patients who have colorectal cancer will receive study drug MM-151 combined with study drug MM-121. The purpose is to continue to evaluate safety and tolerability of dose found in Part 1 as well as to evaluate response of patient’s body and cancer to this combination of study drugs.

Status: Accepting New Patients
Principal Investigator: Benedito Carneiro

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Young Chae

A Phase IB Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYl719 in Adult Patients with Selected Advanced Solid Tumors

The main purpose of this study is to see what effect, good and/or bad, MEK162 and BYL719 given together has on certain advanced solid tumors.

Status: Accepting New Patients
Principal Investigator: Young Chae

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: John Kalapurakal

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

last updated: Sat - June 25, 2016 - 02:30 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.